作者
С. С. Маркин,Маркин Сергей Сергеевич,А М Семенов,А М Семенов,E V Arzamascev,Е В Арзамасцев,В. А. Марков,В. А. Марков,Е. В. Вышлов,Е. В. Вышлов,А А Низов,А А Низов,С Б Аксентьев,С Б Аксентьев,Э. А. Пономарев,Э. А. Пономарев,Г. Н. Гридасов,Г. Н. Гридасов,Petr Lebedev,Petr Lebedev,О. Л. Барбараш,О. Л. Барбараш,В. В. Кашталап,В. В. Кашталап
摘要
Fortelyzin is new fibrinselective thrombolytic agent, gene-modified staphylokinase. This clinical trial showed that Fortelyzin and Actilyse are comparative effective thrombolytic by rate achieve TIMI grade reperfusion in patients with acute myocardial infarction. In the Actilyse patients group the fibrinogen level decreased more intensive then in Fortelyzin group. The safety was similar in both groups.
PDF的下载单位、IP信息已删除
(2025-6-4)
大力的灵雁
无极微光
鸟兽兽
WTKKKL
tiptip
乐空思
lizishu
Semy
蓝天
pluto
手机
嘉心糖
干净的琦
Criminology34
pcr163
SuiWu
邓佳鑫Alan
乐观秋荷
学术文献互助
cc2004bj
皖公网安备34019202002308